Barclays PLC Acquires 43,897 Shares of Aura Biosciences, Inc. (NASDAQ:AURA)

Barclays PLC raised its stake in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 256.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 61,010 shares of the company's stock after buying an additional 43,897 shares during the quarter. Barclays PLC owned 0.12% of Aura Biosciences worth $544,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. American Century Companies Inc. acquired a new stake in shares of Aura Biosciences during the 2nd quarter valued at about $119,000. SG Americas Securities LLC acquired a new stake in Aura Biosciences in the third quarter valued at approximately $169,000. Rhumbline Advisers grew its position in Aura Biosciences by 39.6% in the second quarter. Rhumbline Advisers now owns 63,483 shares of the company's stock worth $480,000 after acquiring an additional 18,011 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Aura Biosciences by 14.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company's stock worth $487,000 after purchasing an additional 8,194 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Aura Biosciences by 26.3% during the 2nd quarter. Renaissance Technologies LLC now owns 72,100 shares of the company's stock valued at $545,000 after purchasing an additional 15,000 shares in the last quarter. Hedge funds and other institutional investors own 96.75% of the company's stock.

Insider Transactions at Aura Biosciences

In other news, insider Janet Jill Hopkins sold 11,822 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.36, for a total value of $110,653.92. Following the completion of the transaction, the insider now directly owns 151,693 shares of the company's stock, valued at approximately $1,419,846.48. This represents a 7.23 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Los Pinos Elisabet De sold 9,200 shares of the business's stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $10.74, for a total value of $98,808.00. Following the completion of the sale, the insider now directly owns 320,647 shares in the company, valued at approximately $3,443,748.78. This represents a 2.79 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,575 shares of company stock valued at $215,401. 5.40% of the stock is owned by corporate insiders.

Aura Biosciences Price Performance

AURA stock traded up $0.10 on Friday, reaching $7.77. 112,088 shares of the company were exchanged, compared to its average volume of 146,793. Aura Biosciences, Inc. has a 12 month low of $6.63 and a 12 month high of $12.38. The stock's fifty day moving average price is $8.62 and its 200 day moving average price is $8.89. The firm has a market capitalization of $388.11 million, a PE ratio of -4.49 and a beta of 0.30.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.02. As a group, research analysts expect that Aura Biosciences, Inc. will post -1.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on AURA shares. Cowen reissued a "buy" rating on shares of Aura Biosciences in a research report on Friday, October 18th. Scotiabank raised their price objective on Aura Biosciences from $20.00 to $23.00 and gave the company a "sector outperform" rating in a research note on Friday, October 18th. HC Wainwright reaffirmed a "buy" rating and set a $22.00 target price on shares of Aura Biosciences in a research report on Thursday, November 14th. Finally, BTIG Research boosted their price objective on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a "buy" rating in a research note on Friday, October 18th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $23.00.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.